摘要
目的比较顺铂联合吉西他滨与紫杉醇治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取四川省司法警官总医院2014年5月—2016年5月收治的晚期NSCLC患者168例,随机将患者分为对照组与研究组,各84例。对照组予以顺铂联合紫杉醇治疗,研究组予以顺铂联合吉西他滨治疗,两组患者均持续治疗2个化疗周期。比较两组患者临床疗效、毒副作用发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。研究组患者白细胞计数减少程度优于对照组,血小板计数减少程度差于对照组(P<0.05);两组患者血红蛋白下降、恶心呕吐、脱发、肝功能损伤、肾功能损伤发生情况比较,差异无统计学意义(P>0.05)。结论顺铂联合吉西他滨与紫杉醇治疗晚期NSCLC的临床疗效相当。
Objective To compare the clinical effect of cisplatin combined with gemcitabine and paclitaxel in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods A total of 168 cases of patients with advanced NSCLC were selected from May 2014 to May 2016 in Police Officers General Hospital of Sichuan Province,which were randomly divided into control group and study group,84 cases in each group.Control group was given cisplatin combined with paclitaxel,study group was given cisplatin combined with gemcitabine,both groups were treated for two cycles of chemotherapy.The clinical effect and the toxic and side effects were compared between the two groups.Results There was no significant difference of clinical effect between the two groups（P〉0.05）.The study group of white blood cell count reduction was better than control group,decrease degree of platelet count was worse than control group（P〈0.05）.No significant differences of the incidence of hemoglobin decreasing,nausea and vomiting,alopecia,liver function damage or renal damage was found between the two groups（P〉0.05）.Conclusion Cisplatin combined with gemcitabine has a same efficacy in the treatment of advanced NSCLC with paclitaxel.
出处
《临床合理用药杂志》
2017年第18期5-6,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
肺肿瘤
顺铂
吉西他滨
紫杉醇
治疗结果
Lung neoplasms
Cisplatin
Gemcitabine
Paclitaxel
Treatment outcome
